Prev Next

37.57.301    DEFINITIONS

As used in this subchapter, the following definitions apply:

(1) "Health care facility" means a hospital or other facility licensed by or located in the state of Montana for the purpose of providing health care services, and which provides primary health care services for newborns at birth.

(2) "Newborn" means an infant in the first 28 days of life.

(3) "Newborn screening tests" are screening tests, procedures, or both for the following conditions:

(a) Acylcarnitine Disorders:

(i) Fatty Acid Oxidation Disorders:

(A) Carnitine uptake defect;

(B) Long-chain L-3-OH acyl-CoA dehydrogenase deficiency;

(C) Medium-chain acyl-CoA dehydrogenase deficiency;

(D) Trifunctional protein deficiency; and

(E) Very long-chain acyl-CoA dehydrogenase deficiency;

(ii) Organic Acidemia Disorders:

(A) 3-hydroxy-3-methylglutaryl-CoA lyase deficiency;

(B) 3-Methylcrotonyl-CoA carboxylase deficiency;

(C) β-ketothiolase deficiency;

(D) Glutaric acidemia type I;

(E) Isovaleric acidemia;

(F) Methylmalonic acidemia (Cbl A,B);

(G) Methylmalonic acidemia (mutase deficiency);

(H) Multiple carboxylase deficiency; and

(I) Propionic acidemia;

(b) Amino Acid Disorders:

(i) Argininosuccinic acidemia;

(ii) Citrullinemia type 1;

(iii) Homocystinuria;

(iv) Maple syrup urine disease;

(v) Classic Phenylketonuria; and

(vi) Tyrosinemia type I;

(c) Biotinidase deficiency;

(d) Classical galactosemia;

(e) Congenital adrenal hyperplasia;

(f) Primary congenital hypothyroidism;

(g) Cystic fibrosis;

(h) Hemoglobinopathies, including:

(i) Hb S/β -thalassemia;

(ii) Hb SC disease; and

(iii) Hb SS disease; and

(i) Critical congenital heart disease, including:

(i) hypoplastic left heart syndrome;

(ii) pulmonary atresia;

(iii) tetralogy of Fallot;

(iv) total anomalous pulmonary venous return;

(v) transposition of the great arteries;

(vi) tricuspid atresia;

(vii) truncus arteriosus;

(j) Severe combined immunodeficiency disease; and

(k) Spinal muscular atrophy (SMA).


History: 50-19-202, MCA; IMP, 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03; AMD, 2008 MAR p. 44, Eff. 1/18/08; AMD, 2014 MAR p. 1411, Eff. 7/1/14; AMD, 2015 MAR p. 828, Eff. 7/1/15; AMD, 2021 MAR p. 184, Eff. 3/1/21.

Home  |   Search  |   About Us  |   Contact Us  |   Help  |   Disclaimer  |   Privacy & Security